News

Diabetes treatment lowers PromarkerD risk score:
Results to be presented at Australasian Diabetes Conference

Proteomics International Laboratories Ltd today announces that its collaborative study with Janssen Research & Development, LLC has found a significant reduction in the PromarkerD risk scores of patients with type 2 diabetes taking canagliflozin, an SGLT2-inhibitor diabetes drug.

Results to be presented at the Australasian Diabetes Congress from 11-13 August 2021.

Media Release


Fatal error: Uncaught wfWAFStorageFileException: Unable to save temporary file for atomic writing. in /home/proteomicscom/promarkerd.com/wp-content/plugins/wordfence/vendor/wordfence/wf-waf/src/lib/storage/file.php:35 Stack trace: #0 /home/proteomicscom/promarkerd.com/wp-content/plugins/wordfence/vendor/wordfence/wf-waf/src/lib/storage/file.php(659): wfWAFStorageFile::atomicFilePutContents('/home/proteomic...', '<?php exit('Acc...') #1 [internal function]: wfWAFStorageFile->saveConfig('livewaf') #2 {main} thrown in /home/proteomicscom/promarkerd.com/wp-content/plugins/wordfence/vendor/wordfence/wf-waf/src/lib/storage/file.php on line 35